NASDAQ$SGMO
Sangamo Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported business highlights and financial results for the third quarter of 2022.
Sangamo Therapeutics reported a net loss of $53.2 million, or $0.34 per share, for the third quarter ended September 30, 2022. Revenues for the quarter were $26.5 million. The company continued to advance its clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence.
- Reported data updates from the Phase 1/2 STAAR study’s dose escalation phase for Fabry disease.
- Dosed the sixth patient in the Phase 1/2 PRECIZN-1 study of BIVV003 for sickle cell disease.
- Dosed the second patient in the Phase 1/2 STEADFAST study evaluating TX200 for Renal Transplant Rejection.
- Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial for Hemophilia A.
Headline financials
Revenue & EPS history
Sangamo · Revenue · Quarterly
$26.5M
Forward guidance
Sangamo expects GAAP total operating expenses to be in the range of approximately $315 million to $325 million and non-GAAP total operating expenses to be in the range of approximately $280 million to $290 million for 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
+0.0%
Avg return
Earnings day
+1.5%
Avg return
5 days after
-3.2%
Avg return
30 days after
52%
34 / 65 earnings
Positive
+59.1%
Q1 2017
Best reaction
-39.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -1.3% | -12.0% | — | |
| Q1 2026 | +3.4% | -5.0% | +10.4% | |
| Q3 2025 | -16.1% | -9.1% | -9.1% | |
| Q2 2025 | -5.6% | +12.5% | +14.6% | |
| Q1 2025 | -39.1% | -37.3% | -33.3% | |
| Q4 2024 | -16.2% | -13.9% | -29.7% | |
| Q3 2024 | -9.6% | -24.1% | -29.3% | |
| Q2 2024 | +11.6% | +32.5% | -2.6% | |
| Q1 2024 | +11.7% | +14.0% | +14.0% | |
| Q4 2023 | -9.4% | -1.2% | -37.2% | |
| Q3 2023 | -27.0% | -30.2% | -28.6% | |
| Q2 2023 | -10.3% | -7.7% | -18.8% | |
| Q1 2023 | -0.6% | -6.2% | -21.7% | |
| Q4 2022 | +2.8% | +4.2% | -41.5% | |
| Q3 2022 | -15.0% | -19.0% | -14.3% | |
| Q2 2022 | +8.3% | +9.2% | +15.2% | |
| Q1 2022 | -9.6% | -15.5% | -18.8% | |
| Q4 2021 | +9.7% | +9.3% | +6.9% | |
| Q3 2021 | +20.0% | +14.2% | -11.4% | |
| Q2 2021 | +3.2% | +7.0% | +6.6% | |
| Q1 2021 | -10.7% | -9.4% | -7.4% | |
| Q4 2020 | -9.2% | -2.8% | -2.7% | |
| Q3 2020 | +12.6% | +8.7% | -6.2% | |
| Q2 2020 | +2.4% | +9.1% | -12.3% | |
| Q1 2020 | +12.5% | +15.4% | +27.1% | |
| Q4 2019 | +27.5% | +21.9% | -4.9% | |
| Q3 2019 | -1.3% | +3.4% | +23.3% | |
| Q2 2019 | +1.1% | -5.2% | -10.3% | |
| Q1 2019 | -14.8% | -13.5% | -15.6% | |
| Q4 2018 | +7.8% | +8.2% | +2.4% | |
| Q3 2018 | -22.0% | -24.5% | -20.9% | |
| Q2 2018 | +8.9% | +13.2% | -2.1% | |
| Q1 2018 | -5.8% | -5.5% | +1.2% | |
| Q4 2017 | +12.4% | +5.6% | -2.0% | |
| Q3 2017 | +12.6% | +7.9% | +41.4% | |
| Q2 2017 | +9.2% | +33.3% | +54.6% | |
| Q1 2017 | +59.1% | +90.9% | +65.9% | |
| Q4 2016 | +9.3% | +10.5% | +9.3% | |
| Q3 2016 | +2.7% | -2.7% | -4.1% | |
| Q2 2016 | -26.0% | -26.9% | -34.2% | |
| Q1 2016 | -4.0% | — | — | |
| Q4 2015 | -11.7% | — | — | |
| Q3 2015 | +11.9% | — | — | |
| Q2 2015 | -17.4% | — | — | |
| Q1 2015 | +7.9% | — | — | |
| Q4 2014 | +10.2% | — | — | |
| Q3 2014 | +1.4% | — | — | |
| Q2 2014 | +4.4% | — | — | |
| Q1 2014 | -9.4% | — | — | |
| Q4 2013 | +3.5% | — | — | |
| Q3 2013 | +4.6% | — | — | |
| Q2 2013 | +2.9% | — | — | |
| Q1 2013 | +11.3% | — | — | |
| Q4 2012 | +7.6% | — | — | |
| Q3 2012 | -2.6% | — | — | |
| Q2 2012 | -0.8% | — | — | |
| Q1 2012 | +5.1% | — | — | |
| Q4 2011 | -2.6% | — | — | |
| Q3 2011 | -2.3% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +2.7% | — | — | |
| Q4 2010 | -3.4% | — | — | |
| Q3 2010 | +2.9% | — | — | |
| Q2 2010 | -1.8% | — | — | |
| Q1 2010 | -12.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro